Long-Read Sequencing Market Surges Toward USD 3.1 Billion by 2029

The global long-read sequencing market is experiencing explosive growth as next-generation genomic technologies continue to transform precision medicine, rare disease research, and advanced biological analysis. The market is projected to grow from USD 758 million in 2024 to USD 3,129 million by 2029, registering a remarkable CAGR of 32.8% during the forecast period.

The rapid expansion of the market is driven by the increasing prevalence of complex genetic disorders, growing demand for accurate genome analysis, and technological advancements in third-generation sequencing technologies. Long-read sequencing has become increasingly important for detecting structural variants, analyzing repetitive genomic regions, and improving transcriptome sequencing accuracy.

Unlike conventional short-read sequencing, long-read sequencing technologies provide deeper genomic insights by reading longer DNA fragments, enabling researchers to better understand genetic complexity and disease mechanisms. As applications expand across oncology, rare disease diagnostics, infectious disease research, agriculture, and personalized medicine, demand for high-performance sequencing platforms continues to rise globally.

The market remains highly consolidated, with leading companies such as PacBio, Oxford Nanopore Technologies plc, and Illumina, Inc. dominating the competitive landscape. These companies are actively focusing on product innovation, strategic collaborations, and geographic expansion to strengthen their market presence.

Download PDF brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=140422082

Oxford Nanopore Expands Global Reach Through Strategic Collaborations

Oxford Nanopore Technologies plc is among the most innovative players in the long-read sequencing market, known for its nanopore-based sequencing technology platforms.

The company operates in more than 100 countries and offers sequencing solutions through its Life Science Research Tools segment. Oxford Nanopore’s technology allows real-time analysis of DNA and RNA molecules, making it highly valuable for research, clinical diagnostics, and genomic surveillance applications.

To improve accessibility and adoption, the company uses strategic pricing approaches for flow cells and consumables, targeting academic institutions, research laboratories, and clinical users worldwide.

Oxford Nanopore also continues to strengthen its position through strategic collaborations. In June 2023, the company announced a research collaboration agreement with the National German Initiative to advance rare disease research using nanopore-based genome sequencing technologies.

PacBio Strengthens Portfolio with High-Accuracy Sequencing Systems

PacBio remains a major force in the long-read sequencing market through its advanced HiFi long-read sequencing and Single Molecule Real-Time (SMRT) sequencing technologies.

The company designs and manufactures highly accurate sequencing systems used by pharmaceutical companies, biotechnology firms, universities, research institutions, and government organizations worldwide. PacBio’s sequencing platforms are particularly valued for their ability to provide high accuracy and high-throughput genomic analysis.

The company continues to enhance its product portfolio through continuous innovation. Its Sequel II and Sequel IIe systems offer scalable genomic and transcriptomic sequencing solutions for a wide range of applications.

In February 2024, PacBio launched new high-throughput library preparation kits and optimized workflows specifically designed for its Revio sequencing system. These advancements are expected to improve sequencing efficiency and support large-scale genomic studies.

Illumina Expands into Long-Read Sequencing Innovation

Illumina, Inc., widely recognized as a leader in genome sequencing technologies, is increasingly expanding its capabilities in the long-read sequencing segment.

The company offers sequencing instruments, consumables, and analytical tools designed to streamline genomic analysis across research and clinical applications. Through its equipment and consumables division, Illumina provides advanced long-read sequencing solutions alongside sequencing services under its Service and Other Revenue segment.

Illumina’s ongoing investment in research and development has enabled the company to introduce innovative sequencing technologies with enhanced accuracy and broader application potential.

In March 2023, Illumina launched its first product based on Illumina Complete Long Read technology—Illumina Complete Long Read Prep, Human. The solution is compatible with NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 sequencing systems and is designed for high-performance human whole-genome sequencing applications.

Future Outlook

The future of the long-read sequencing market looks exceptionally promising as genomic research becomes increasingly central to precision healthcare and biomedical innovation. Advances in sequencing chemistry, AI-powered bioinformatics, and scalable genomic analysis platforms are expected to accelerate market growth further.

As demand for comprehensive genomic insights rises across healthcare, agriculture, and pharmaceutical research, long-read sequencing technologies are expected to play a critical role in unlocking new discoveries and enabling personalized treatment approaches. Leading companies are likely to continue investing heavily in innovation, partnerships, and global expansion to capitalize on the rapidly evolving genomics landscape.